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Double-stranded RNA (dsRNA) of viral origin triggers two programs of the innate immunity in virus-
infected cells. One is intended to decrease the rate of host cell protein synthesis and thus to prevent viral
replication. This program is mediated by protein kinase R (PKR) and by RNase L and contributes, eventually,
to the self-elimination of the infected cell via apoptosis. The second program is responsible for the production
of antiviral (type I) interferons and other alarmone cytokines and serves the purpose of preparing naive cells
for the viral invasion. This second program requires the survival of the infected cell and depends on the
expression of antiapoptotic genes through the activation of the NF-kB transcription factor. The second
program therefore relies on ongoing transcription and translation. It has been proposed that PKR plays an
essential role in the activation of NF-kB by dsRNA. Here we present evidence that the dsRNA-induced NF-kB
activity and the expression of beta interferon and inflammatory cytokines do not require either PKR or RNase
L. Our results indicate, therefore, that the two dsRNA-activated programs are separate and can function
independently of each other.
At the cellular level, the innate immune response to viruses
relies on the execution of two apparently conflicting cellular
programs: cell suicide (apoptosis) and survival. The first pro-
gram is probably most efficient for viral infections that are
initiated by a small number of infected cells at a local site of
virus entry. In such case, it seems beneficial (for the organism)
for this first population of infected cells to undergo a rapid
process of self-elimination through apoptosis, thus preventing
further infection. That this first line of antiviral defense is
widely used is evident from the multitude of antiapoptotic
strategies employed by viruses. Viral genomes encode a grow-
ing number of apoptosis-inhibiting proteins, such as the ade-
novirus E1B protein (45, 72), the baculovirus p35 protein (5,
44, 58), the cowpox virus CrmA protein (17, 63), the poxvirus
and gammaherpesvirus v-FLIP proteins (66), and others (for a
review, see reference 62). Genetic evidence from mice (48)
(see below) demonstrates that inhibition of apoptosis by the
virus is critical for the virulence of encephalomyocarditis virus
(EMCV), a picornavirus that is lethal to infected mice.
A common viral intermediate that is recognized by specific
cellular sensory systems to trigger apoptosis is viral double-
stranded RNA (dsRNA). The best-characterized effect of
dsRNA on cells is the inhibition of protein synthesis in host
cells. The cellular dsRNA-detecting systems that are responsi-
ble for the translational inhibition in response to viral infection
are the dsRNA-activated protein kinase (PKR) and the cou-
pled 2-5 oligoadenylate synthase/RNase L system. PKR (39) is
a dormant enzyme directly activated by binding of dsRNA (for
recent reviews, see references 28 and 73). A major substrate of
PKR is the a-subunit of the eukaryotic translation initiation
factor 2 (eIF-2a) (22, 35). Phosphorylation of eIF-2a greatly
reduces the rate of initiation of translation (50). The 2-5 oli-
goadenylate synthase/RNase L system is composed of a family
of dsRNA-dependent enzymes known as 29-59 oligoadenylate
synthetases (OAS) (7, 24, 43) and the dormant cytosolic RNase
L (82). Upon dsRNA binding, OAS produce unusual second
messengers, short 29-59-linked oligoadenylates (2-5A), which,
in turn, specifically bind to and activate RNase L (41). Acti-
vated RNase L cleaves diverse RNA substrates, including 18S
and 28S rRNA, thus inhibiting cellular protein synthesis (26,
51, 52, 74). Fibroblasts from mice nullizygous for both PKR
and RNase L alleles are unable to inhibit protein synthesis
when challenged with dsRNA (26), thus demonstrating that
these two enzymes are both required and sufficient for the
translational inhibition caused by dsRNA. Recently, both PKR
(2, 3, 15, 20, 34, 53, 77) and RNase L (7–9, 13, 83, 85) have
been found to mediate dsRNA-induced apoptosis. The mech-
anisms of involvement of PKR and RNase L in the dsRNA-
triggered apoptosis are, however, poorly understood. Consid-
ering the role of both PKR and RNase L in inhibiting protein
synthesis, one obvious candidate for a death-inducing signal is
the impaired process of translation. A sustained inhibition of
protein synthesis is sufficient to trigger apoptosis in cells in a
way that is independent of the particular means of achieving
translational inhibition (27). However, other (more direct)
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mechanisms of dsRNA-induced cell death, which are indepen-
dent of the state of cellular translation, are very likely to exist.
The second dsRNA-initiated program for antiviral defense
involves the production and secretion by the infected cells of
alarmone cytokines, the best-studied examples of which are the
alpha, beta, and omega interferons, [for reviews, see references
16 and 54]). The importance of these interferons for conferring
viral resistance to naive cells has been demonstrated by the
strong sensitivity to viral infections of mice lacking the com-
mon subunit of the alpha, beta, and omega interferon receptor
(40). It is thought that these interferons exert their pleiotropic
antiviral actions by preparing cells to interfere with multiple,
virus-specific steps of the viral replication cycle, including viral
entry, uncoating, transcription, RNA stability, maturation, as-
sembly, and release (for a review, see reference 54). Interfer-
ons are also important for the ability of adaptive immunity to
take over the innate immune response in combating the virus.
For instance, mice lacking the interferon alpha, beta, and
omega receptor are unable to mount a cytotoxic T-lymphocyte
response to infection with lymphocytic choriomeningitis virus
(40).
A crucial step in the virus-induced beta interferon produc-
tion appears to be its transcriptional upregulation by viral
dsRNA (for a review, see reference 37). The highly specific
transcriptional induction of the beta interferon gene by viruses
has been best studied for the human beta interferon gene
promoter/enhancer region. This region contains a set of regu-
latory elements called positive regulatory domains (PRDI to
PRDIV). PRDII, PRDI-III, and PRDIV bind the transcription
factors NF-kB, IRF-1 (or IRF-3), and ATF-2/c-Jun, respec-
tively (for a review, see reference 37). Importantly, NF-kB
appears to be absolutely required for the virus-induced activa-
tion of the human beta interferon promoter (18, 64, 65).
For the second (interferon-dependent) program of innate
antiviral immune response to be successful, the proapoptotic
response of the infected cells must be suppressed, at least for
the time required to complete the production and secretion of
alarmone cytokines. Interestingly, genetic evidence strongly
suggests that NF-kB not only plays an important role in the
production of beta interferon but also is essential in suppress-
ing virus-induced apoptosis. Mice engineered to lack the p50/
NF-kB1 subunit of NF-kB (see below) are resistant to infec-
tion with EMCV (48, 49). This surprising result (which seems
to contradict the important role of NF-kB in combating viral
infections) is explained by the discovery that EMCV-infected
cells from p50/NF-kB1-nullizygous mice (as well as from mice
engineered to lack the other common subunit of NF-kB, p65/
RelA [see below]) undergo very rapid apoptosis before the
virus could reproduce (48). These results demonstrate the ap-
optosis-suppressing function of NF-kB in EMCV infection.
The antiapoptotic role of NF-kB is thought to result from the
NF-kB-dependent transcriptional activation of several apopto-
sis-inhibiting genes, such as the genes encoding the inhibitor-
of-apoptosis proteins (IAPs; for a review, see reference 32)
IAP-1, IAP-2, and X-linked IAP (X-IAP1) (12, 55, 70), Bcl-XL
(10, 33, 68), and A1/Bfl1 (33, 57, 69, 86).
How is NF-kB activated in general and by viruses and
dsRNA in particular? NF-kB is a collective name for a group
of homo- and heterodimeric transcriptional regulators (activa-
tors or repressors) consisting in vertebrates, of the polypeptide
products of the p50/p105(nfkb1), p52/p100(nfkb2), c-rel, relA,
and relB genes (for reviews, see references 21 and 42). In
mammalian cells, the most common NF-kB complex is the
p50/NF-kB1–p65/RelA heterodimer, and it is this combination
that is most commonly referred to as NF-kB proper (42). An
essential role in the regulation of NF-kB is played by a family
of inhibitory proteins, collectively termed IkBs (the family en-
compasses IkB-a, IkB-b, IkB-e , and Bcl-3 [for a review, see
reference 31]). In nonstimulated cells, IkBs sequester the p50/
NF-kB1–p65/RelA heterodimer in the cytoplasm, thus pre-
venting it from localizing in the nucleus and stimulating the
transcription of NF-kB-dependent genes (for a review, see
reference 31). With the notable exception of UV radiation, a
potent NF-kB activator, most stimuli that activate NF-kB (in-
cluding viruses and dsRNA) cause the phosphorylation of
serine residues 32 and 36 in IkB-a (and of the corresponding
serine residues in IkB-b). The phosphorylation of IkB causes
its rapid polyubiquitinylation and degradation by the 26S pro-
teasome, thus releasing NF-kB and allowing it to translocate to
the nucleus (most extensively reviewed in references 30, 31,
and 80). A multicomponent IkB kinase (IKK) complex has
been purified, molecularly cloned, and found to consist of two
homologous catalytic subunits (IKK1/a and IKK2/b) (14, 38,
81) and a noncatalytic subunit (IKKg, also known as NEMO)
(75). Genetic inactivation of IKK in mice demonstrated that
IKK2/b and IKKg (but not IKK1/a) are required for the IkB
phosphorylation and subsequent NF-kB activation in response
to most agents (25, 36, 46, 59, 61). Due to the lack of suitable
targeted gene inactivation models, however, the modes of up-
stream regulation of IKK activity are currently completely un-
known, even though several kinases have been proposed to act
upstream of IKKs. For instance, in striking contrast to all
experimental evidence concerning the role of PKR in trigger-
ing the protein synthesis-inhibiting and proapoptotic program
of antiviral innate immunity, this kinase has been proposed to
be a major mediator of virus- and dsRNA-induced activation
of NF-kB. Using mouse embryonic fibroblasts (MEF) and 3T3-
like fibroblast cell lines from one of the two published PKR
genetic knockouts (76), several groups found these cells to be
deficient in dsRNA-induced NF-kB activation, thus postulat-
ing an important role for this kinase in activating NF-kB in
response to viruses (11, 19, 79).
We considered that this postulated role of PKR in dsRNA-
induced NF-kB activation ultimately imposes the paradoxical
situation that the same dsRNA-sensing molecule (PKR) would
trigger the execution of the two opposing antiviral programs in
the same cell: the program that attempts to eliminate the
infected cell through translational inhibition and apoptosis and
the program that attempts to suppress apoptosis through
NF-kB activation. To resolve this paradox, we have employed
a panel of primary MEF or 3T3-like cell lines from two inde-
pendent successful attempts to inactivate the PKR gene in
mice (1, 76), from the RNase L-deficient mice (83), and from
mice with a double deficiency in both the PKR and the RNase
L genes (26, 84). Our study demonstrates that neither PKR nor
RNase L is required for the activation of NF-kB by dsRNA or
EMCV. Furthermore, we found that the ability of dsRNA to
stimulate the expression of beta interferon and of the inflam-
matory cytokines interleukin-6 (IL-6) and tumor necrosis fac-
tor alpha (TNF-a) was also independent of the presence of
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PKR. Thus, the “translational inhibition/pro-apoptotic pro-
gram” and the “biosynthetic/anti-apoptotic program,” each
triggered by viral dsRNA, appear to be mechanistically sepa-
rate and to function independently of one another.
MATERIALS AND METHODS
Chemicals. Lipofectin reagent was from Gibco BRL/Life Technologies. pI-pC
was from Midland Certified Reagent Co. and was stored at 220°C as a 10-mg/ml
stock solution in double-distilled deionized water. The proteasome inhibitors
benzyloxycarbonylleucyl-leucyl-leucine aldehyde (MG 132) and benzyloxycar-
bonyliso-leucyl-glutamyl(OtBu)-alanyl-leucine aldehyde (proteasome inhibitor
I) were purchased both from Alexis Biochemicals and from Calbiochem, and
there was no detectable difference in their activities. Recombinant human
TNF-a was from R&D Systems. All radiochemicals were from DuPont NEN
Research Products.
Cells. All cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% calf serum (HyClone, Logan, Ut.). pkr1/1
(EX12) and pkr0/0(EX12) MEF have been described previously (1) and were
referred to there as pkr1/1 and pkr0/0 cells. pkr1/1(EX213) and pkr0/0(EX213)
MEF were described previously (76) and were also referred to there as pkr1/1
and pkr0/0 cells. The rnasel1/1/pkr1/1, rnasel2/2/pkr1/1, and rnasel2/2/pkr2/2
3T3-like fibroblasts were described previously (84) and are referred to here by
the same names as in reference 26.
Lipofectin-mediated delivery of pI-pC. The procedure for treatment of cells
with pI-pC was the same as described in reference 26. For each milliliter of final
volume of Lipofectin mixture, an initial concentrated mixture (containing Lipo-
fectin and pI-pC) was prepared in one-quarter of the final volume (250 ml). To
this end, 10 ml of Lipofectin (1 mg/ml) was added to serum- and antibiotic-free
DMEM and mixed, and the desired amount of pI-pC was added (in a volume of
250 ml). This mixture was left for 10 min at room temperature. Finally, the
remaining three-quarters of the final volume (750 ml) was added. Before the
application of the Lipofectin–pI-pC mixtures, the cells were washed once with
serum-free DMEM.
Preparation of cell lysates for immunoblot analysis. To avoid any possible
dephosphorylation or proteolytic degradation of the proteins of interest, the cells
were typically harvested by aspirating the cell culture medium, scraping the cells
directly on the tissue culture plate in 23 sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) sample-loading buffer, and subjecting them to
heat denaturation at 95°C for 5 min. Cell lysates were stored at 270°C.
Antibodies and immunoblot analyses. The antibodies against IkB-b (C-20),
phospho-(serine-32)–IkB-a (B-9), PKR (M-515 and D-20), and p65/RelA (C-20)
and the blocking peptide solutions used in the experiment in Fig. 3 (p65/RelA
C-20 peptide and MEKK1 C-22 peptide) were from Santa Cruz Biotechnologies.
For the antibody blocking, 1 volume of the anti-p65/RelA antibody was prein-
cubated with 5 volumes of the respective blocking peptide solution for 6 h at
room temperature. The antibody against IkB-a (13996E) was from Pharmingen.
The antibodies against the dually phosphorylated forms of JNK and p38a mito-
gen-activated protein (MAP) kinase were from New England BioLabs. The
antibody against the phosphorylated form of eIF-2a was from Research Genet-
ics. The electrophoretic separation of proteins in SDS-PAGE and electrotransfer
to a polyvinylidene difluoride membrane (Millipore) were performed using stan-
dard procedures. Immunoprobing with specific antibodies and enhanced chemi-
luminescence detection (DuPont NEN Research Products) were performed as
specified by the respective manufacturers.
Immunocytochemical staining of p65/RelA. Cells were grown on Thermanox
coverslips (Nunc). After the appropriate treatments, the cells were fixed in cold
(220°C) methanol for 5 min, dried, and stored at 220°C. Blocking was per-
formed with 1.5% normal goat serum in PBS for 1 h followed by incubation with
the primary antibody (anti-p65/RelA [C-20 from Santa Cruz] at a 1:800 dilution
in PBS with 1.5% serum) for 1 h. After the cells were washed in PBS, incubation
with secondary antibody was performed with biotinylated anti-rabbit immuno-
globulin G (1:500 dilution in PBS with 1.5% serum) for 1 h, followed again by
washing. Endogenous peroxidase activity was quenched with 2% hydrogen per-
oxide in PBS for 30 min. After being washed, the cells were incubated with
VectaStain Elite ABC reagent (Vector Laboratories) for 1 h. Finally, the cells
were washed, incubated with diaminobenzidine (Sigma) until the desired stain
intensity developed, and rinsed with water. Photographs were taken using a
CoolSnap digital camera mounted on a Zeiss microscope.
EMSA. Nuclear extracts were prepared and used in electrophoretic mobility
shift assays as described in references 4 and 56. Briefly, cells were collected by
scraping in ice-cold PBS, sedimented, and resuspended in 100 ml of lysis buffer
(10 mM HEPES [pH 7.9], 1 mM EDTA, 60 mM KCl, 0.5% Nonidet P-40
[NP-40], 1 mM dithiothreitol [DTT], protease inhibitor cocktail [Roche Molec-
ular Biochemicals]). After 5 min on ice, nuclei were sedimented at 1,200 3 g for
5 min. The supernatant was used as the cytoplasmic extract. The nuclei were
washed with lysis buffer without NP-40 and suspended in 100 ml of nuclear buffer
(250 mM Tris-HCl [pH 7.8], 60 mM KCl, 1 mM DTT, protease inhibitor cock-
tail). Nuclei were lysed by three cycles of freezing and thawing in liquid nitrogen
and ice. The nuclear extracts were cleared by centrifugation at 13,000 3 g for 15
min. EMSAs were done as described in reference 4: the binding reaction was
performed in a volume of 20 ml with 5 mg of nuclear protein in a buffer containing
12 mM HEPES (pH 7.8), 62.5 mM Tris-HCl (pH 7.8), 60 mM KCl, 0.6 mM
EDTA, 12% glycerol, 5 mM DTT, 2 mg of bovine serum albumin, and 1 mg of
poly(dI-dC). 32P-radiolabeled consensus double-stranded NF-kB-binding oligo-
nucleotide (59-AGT TGA GGG GAC TTT CCC AGG C-39) or the correspond-
ing oligonucleotide with a single-base point mutation (59-AGT TGA GGC GAC
TTT CCC AGG C-39) from Santa Cruz Biotechnologies were used as probes.
For the competition experiments, a consensus double-stranded p53-binding oli-
gonucleotide (59-TAC AGA ACA TGT CTA AGC ATG CTG GGG-39) from
Santa Cruz Biotechnologies was used as a nonspecific competitor.
RNA isolation and Northern blot detection of mRNA. Total cellular-RNA was
isolated using TRIzol reagent (GIBCO BRL) as specified by the manufacturer.
The multiprobe detection of beta interferon, IL-6, and TNF-a was performed
using a RiboQuant RNase protection assay kit with a mCK-3b multiprobe tem-
plate (Pharmingen) as specified by the manufacturer. A 10-mg portion of total
RNA was used.
Determination of IL-6 production. The production of IL-6 was determined
quantitatively using the Quantikine M mouse IL-6 enzyme-linked immunosor-
bent assay (R&D Systems) as specified by the manufacturer and as described
previously (26).
RESULTS
EMCV infection causes the proteolytic degradation of IkB-b
in both pkr1/1 and pkr0/0 MEF. To investigate the possible role
of PKR in virus-induced activation of NF-kB, we employed
primary fibroblasts derived from wild-type (pkr1/1) or pkr0/0
mouse embryos established in the laboratory of one of us (1).
Since the inactivation of PKR alleles in these mice was
achieved through a homologous recombination event involving
exon 12 of the PKR gene, these MEF are referred to hereafter
as pkr1/1(EX12) and pkr0/0(EX12), respectively. Later, when
MEF from a different PKR knockout (inactivating the PKR
gene exons 2 and 3) (76) are used (see below), these cell will be
referred to as pkr1/1(EX213) and pkr0/0(EX213), respec-
tively. At 2 h after infection with EMCV, there was a detect-
able decrease in the steady-state levels of IkB-b both in the
pkr1/1(EX12) and in the pkr0/0(EX12) MEF (Fig. 1A, lanes 3
and 7). Four hours after the infection, IkB-b levels in both the
pkr1/1(EX12) and the pkr0/0(EX12) MEF were reduced to a
minor fraction of those in the control cells (compare lanes 2
and 6 with lanes 4 and 8). The absence of PKR in the pkr0/0
(EX12) MEF was confirmed using two independent PKR an-
tisera (compare lanes 1 to 4 with lanes 5 to 8). At 4 h after the
infection with EMCV, the levels of PKR in the wild-type MEF
were reduced (lane 4), probably reflecting the overall inhibi-
tion of protein synthesis and the subsequent turnover of PKR
protein in these cells.
dsRNA triggers the phosphorylation, polyubiquitinylation,
and proteosome-mediated degradation of IkBs in both pkr1/1
(EX12) and pkr0/0(EX12) MEF. The degradation of IkB-b in
EMCV-infected MEF was paralleled by the phosphorylation
of the stress-activated protein kinases (SAPK) p38a MAP ki-
nase (Fig. 1A, lanes 3, 4, 7, and 8), JNK1, and JNK2 (not
shown). Previously, we reported that SAPK are potently acti-
vated by dsRNA (26). We set out, therefore, to investigate the
specific role of dsRNA in virus-induced activation of NF-kB,
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independent of viral proteins that, in many cases, also modu-
late NF-kB activity. To achieve this goal, we used pI-pC, a
synthetic dsRNA, which was delivered into cells via lipofection
(see Materials and Methods). First, we set out to confirm that
the deletion of exon 12 of PKR in the pkr0/0(EX12) MEF
resulted in a complete abrogation of PKR activity. Treatment
of pkr1/1(EX12) MEF with pI-pC (hereafter referred to as
dsRNA) caused the phosphorylation of eIF-2a at serine-51
(Fig. 1B, lane 3). Identically treated pkr0/0(EX12) MEF failed
to display the phosphorylation of eIF-2a at serine-51 (lane 6).
In contrast to these results and in agreement with our previous
findings (26), the p38a MAP kinase was phosphorylated in
response to dsRNA both in the PKR-containing and in the
PKR-deficient cells (lanes 3 and 6). We concluded, therefore,
that the deletion of exon 12 of PKR in the pkr0/0(EX12) MEF
has resulted indeed in a complete abrogation of PKR activity.
We next addressed the dsRNA-induced signaling to NF-kB.
Treatment of either pkr1/1(EX12) or pkr0/0(EX12) MEF with
pI-pC for 1 h resulted in a detectable increase in serine-32
phosphorylation of IkB-a as measured by immunoblot analysis
using an antibody recognizing specifically only the serine-32-
phosphorylated form of IkB-a (Fig. 2A, upper panels, lanes 2
and 4). Consistent with the role of IkB-a phosphorylation in its
degradation by the ubiquitin-proteosome system (for a review,
see reference 31), the levels of IkB-a were significantly re-
duced in dsRNA-treated cells (lower panels, lanes 2 and 4). To
FIG. 1. (A) EMCV-induced degradation of IkB-b. pkr1/1(EX12)
and pkr0/0(EX12) MEF (;2 3 106 cells) were infected, where indi-
cated, with EMCV (100 PFU per cell) in 2 ml of serum-free medium
for 1 h, after which time the excess virus was removed by extensive
washing of the cells with serum-free medium. The cells were further
incubated in serum-free medium. At 2 or 4 h after the removal of the
extracellular virus, the mock-infected or infected cells were harvested
and the cell lysates were processed for the immunoblot detection of
IkB-b (top panel) as described in Materials and Methods. The mem-
branes were stripped and reprobed consecutively with an anti-phos-
phorylated p38 MAP kinase antibody (second panel from top) and
with the M-515 (third panel from top) and D-20 (bottom panel) PKR
antisera. A nonspecific band recognized by the D-20 antibody is indi-
cated by an asterisk. (B) Lack of PKR activity in the pkr0/0(EX12)
MEF. pkr1/1(EX12) and pkr0/0(EX12) MEF were left untreated (Co)
or were treated with Lipofectin (LF) alone or with pI-pC (10 mg/ml) in
the presence of Lipofectin (LF 1 dsRNA). At 3 h after the treatments,
the phosphorylation states of eIF-2a and p38a MAP kinase were
assessed in immunoblot analyses.
FIG. 2. dsRNA-triggered phosphorylation, polyubiquitinylation,
and proteosome-mediated degradation of IkBs in both pkr1/1(EX12)
and pkr0/0(EX12) MEF. (A) pkr1/1(EX12) and pkr0/0(EX12) MEF
were treated with Lipofectin alone (lanes Control) or with pI-pC (10
mg/ml) in the presence of Lipofectin (lanes dsRNA). Note that the
same procedure for Lipofectin treatment (with or without pI-pC) ap-
plies to all experiment presented in Fig. 2 to 9 and is described in
Materials and Methods. At 1 h after the treatment, the cells were
harvested and processed for immunoblot analysis of IkBa using either
a phospho-(Ser32)-IkBa-specific antibody (upper panels) or an IkBa-
specific antibody (lower panels). Treatment of cells with Lipofectin
does not affect IkBb or any other NFkB-related signaling pathway
investigated in this work (data not shown). (B) pkr1/1(EX12) and
pkr0/0(EX12) MEF were treated as in panel A, except that, where
indicated, the cells were pretreated for 25 min with benzyloxycarbon-
yliso-leucyl-glutamyl(OtBu)-alanyl-leucine aldehyde (IEAL), benzy-
loxycarbonyl-leucyl-leucyl-leucine aldehyde (LLL), or the respective
solvents for each of them, methanol (MeOH) or dimethyl sulfoxide
(DMSO). IkBb steady-state levels were monitored in an immunoblot
analysis.
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investigate whether IkB-b is also degraded by the ubiquitin-
proteosome system in response to dsRNA, we employed two
peptide proteosome inhibitors, benzyloxycarbonylleucyl-leucyl-
leucine aldehyde (labeled LLL in Fig. 2B) and benzyl-
oxycarbonyliso-leucyl-glutamyl(OtBu)-alanyl-leucine aldehyde
(labeled IEAL in Fig. 2B). Treatment of either pkr1/1(EX12)
or pkr0/0(EX12) MEF with dsRNA for 1 h led to a detectable
reduction in the steady-state levels of IkB-b in both the pkr1/1
(EX12) and the pkr0/0(EX12) MEF (Fig. 2B, narrow panels,
lane 6). Pretreatment of the cells with either of the two pro-
teosome inhibitors prevented the dsRNA-induced degradation
of IkB-b (narrow panels, lanes 9 and 10). Furthermore, in the
presence of both dsRNA and the proteasome inhibitors, the
cells accumulated multiple anti-IkB-b-immunoreactive bands
with reduced mobility in SDS-PAGE (wide panels, lanes 9 and
10; note that the wide panels represent a longer film exposure
of the same immunoblots presented in the narrow panels). The
appearance of these novel forms of anti-IkB-b immunoreac-
tivity with reduced mobility is consistent with unimpaired levels
of dsRNA-induced polyubiquitinylation of IkB-b but a blocked
polyubiquitinylation-induced degradation of IkB-b by the pro-
teasome. Importantly, identical effects on the IkBs of these
proteasome inhibitors were observed in cells stimulated with
TNF-a, a well-established inducer of proteasome-mediated
degradation of IkBs (reference 67 and data not shown). None
of the dsRNA-induced effects on IkBs (phosphorylation,
polyubiquitinylation, and proteasome-dependent degradation)
appeared to require the presence of PKR. Neither single-
stranded RNA (pI or pC), nor dsDNA (p[d(IC)]) had any
effect on IkB-b or IkB-a (data not shown), indicating that the
effects observed using pI-pC represent a bona fide dsRNA
response. Despite the limited ability to compare the behavior
of IkB-b and IkB-a in the same assay, the results shown in Fig.
2 favor the conclusion that both IkBs are addressed by dsRNA-
induced signal transduction pathways in a similar manner.
dsRNA-induced IkB degradation coincides with transloca-
tion of NF-kB to the nucleus, independent of the presence or
the absence of PKR. To investigate and determine conclusively
if PKR may be required for a functional activation of NF-kB
downstream of IkB phosphorylation and degradation, we em-
ployed pkr1/1(EX12) and pkr0/0(EX12) MEF and pkr1/1
(EX213) and pkr0/0(EX213) MEF (76). First, we demon-
strated that in the pkr1/1(EX213) and pkr0/0(EX213) MEF,
the Lipofectin-mediated delivery of dsRNA led to the degra-
dation of IkB-a and IkB-b similarly to the effect of dsRNA on
the pkr1/1(EX12) and pkr0/0(EX12) MEF [data not shown, but
see also Fig. 8, demonstrating the dsRNA-induced IkB-b deg-
radation in embryonic fibroblasts derived from pkr0/0(EX213) 3
rnasel2/2 mice (84)]. We then performed immunocytochemical
staining of control (Lipofectin-treated) and dsRNA-treated
MEF (EX12 and EX213) by using an antibody recognizing the
p65/RelA subunit of NF-kB. As shown in Fig. 3A, p65/RelA
displayed a typical cytoplasmic distribution in the control
pkr1/1(EX213) MEF. At 3 h after dsRNA treatment, a strong
immunopositive signal appeared in the nucleus (Fig. 3B), in-
dicative of induced nuclear translocation of NF-kB. Preincu-
bation of the antibody with a p65/RelA peptide epitope abol-
ished the immunocytochemical staining (Fig. 3C and D),
whereas the preincubation with an irrelevant peptide epitope
had no effect on the ability of the antibody to stain cells (Fig.
3E and 3F). An identical pattern of nuclear staining was de-
tected after treatment of cells with TNF-a (data not shown).
Thus, the method used in the experiment in Fig. 3 appeared to
represent faithfully the translocation of p65/RelA following a
signal that triggers IkB degradation. Using this method, we
next demonstrated that, both in the pkr0/0(EX213) MEF and
in the pkr0/0(EX12) MEF, dsRNA led to a nuclear transloca-
tion of p65/RelA in a manner identical to the ability of dsRNA
to cause p65/RelA nuclear translocation in the respective wild-
type cells (Fig. 4). Thus, the evidence obtained using MEF
from two independent approaches to generate PKR-null mice
demonstrates that PKR is not an essential kinase for the mi-
gration of NF-kB to the nucleus following dsRNA-induced IkB
degradation.
PKR deficiency does not affect the specific DNA-binding
activity of NF-kB. Since a fraction of PKR has been found in
the nucleus (29), it was not unreasonable to investigate
whether PKR might be involved in modulating NF-kB activity
at the level of the DNA-binding ability of this transcription
factor. Nuclear extracts from wild-type MEF (EX12) treated
with either dsRNA or TNF-a displayed a prominent DNA-
FIG. 3. dsRNA-induced nuclear translocation of NFkB. pkr1/1
(EX12) MEF were treated with Lipofectin alone (A, C, and E) or with
pI-pC (10 mg/ml) in the presence of Lipofectin (B, D, and F). At 3 h
after the treatment, the cells were fixed and immunostained with an
antibody recognizing the p65/RelA subunit of NFkB, as described in
Materials and Methods. An irrelevant peptide (representing an
epitope corresponding to the C-terminal domain of MEKK1) or a
specific blocking peptide were used (as described in Materials and
Methods) in panels E and F and in panels C and D, respectively.
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binding activity in EMSA using an NF-kB-specific oligonucle-
otide probe (Fig. 5, lanes 1 to 3). This DNA-binding activity
was successfully competed by a 100-fold molar excess of the
same unlabeled probe (lanes 4 to 6) but was not competed by
a 100-fold molar excess of an irrelevant oligonucleotide (lanes
7 to 9). Furthermore, the DNA-binding activity was super-
shifted when the nuclear extracts were preincubated with the
anti-p65/RelA antibody (lane 10), thus leading to the positive
identification of NF-kB in the retarded protein-oligonucle-
otide complex. Therefore, the EMSA appeared to be a suitable
assay to study the DNA-binding activity of NF-kB. As shown in
Fig. 6A, treatment of either pkr1/1(EX12) or pkr0/0(EX12)
MEF with dsRNA led to the appearance in the nuclear extracts
of NF-kB with similar DNA-binding activity that did not re-
quire the presence of PKR (Fig. 6A, compare lanes 3 and 4
with lanes 8 and 9). Furthermore, cells treated with TNF-a
displayed a similar DNA-binding activity that was independent
of PKR (lanes 5 and 10). With either dsRNA or TNF-a treat-
ment, the induced DNA-binding activity failed to form on an
oligonucleotide probe with a single nucleotide substitution
(Fig. 6A, second panel from the bottom), further demonstrat-
ing that NF-kB is the major (and possibly the only) DNA-
binding activity in the complex. The corresponding cytosolic
extracts demonstrated the presence of PKR only in the pkr1/1
(EX12) but not in the pkr0/0(EX12) MEF (bottom panel).
The results presented in Fig. 2 to 6A contrast with the
findings of others (11, 76, 79), who reported that fibroblasts
deficient in PKR failed to respond to dsRNA with NF-kB
activation. To investigate whether the different modes of
dsRNA delivery used by us and by others are responsible for
these differences, we compared the responses of MEF either to
10 mg of pI-pC per ml in the presence of Lipofectin or to 100
or 500 mg of pI-pC per ml without Lipofectin (as used by
Zamanian-Daryoush et al. 79). Using the EMSA, we observed
that both in the presence and in the absence of Lipofectin,
dsRNA was able to induce the NF-kB DNA-binding activity in
the PKR-containing and in the PKR-deficient cells (Fig. 6B).
The dsRNA-induced accumulation of the mRNA for beta
interferon occurs in the absence of PKR. Previously, Yang et
al. (76) and Chu et al. (11) found that dsRNA (applied without
FIG. 4. dsRNA-induced nuclear translocation of NFkB indepen-
dent of the presence or the absence of PKR. pkr1/1(EX213), pkr0/0
(EX213), pkr1/1(EX12), or pkr0/0(EX12) MEF were treated with Li-
pofectin alone (A, C, E, and G) or with pI-pC (10 mg/ml) in the
presence of Lipofectin (B, D, F, and H). At 3 h after the treatment, the
cells were fixed and immunostained with an antibody recognizing the
p65/RelA subunit of NFkB as in Fig. 3.
FIG. 5. dsRNA- and TNF-a-induced specific DNA-binding activity
of NFkB. pkr1/1(EX12) MEF were treated with Lipofectin alone
(lanes Co), with pI-pC (10 mg/ml) in the presence of Lipofectin (lanes
dsRNA), or with TNF-a (lanes TNF). At 3 h after either Lipofectin or
dsRNA treatments or 20 min after the TNF-a treatment, the cells were
harvested and nuclear extracts were prepared as described in Materials
and Methods. EMSAs were performed as described in Materials and
Methods. Where indicated, a 100-fold molar excess of either the spe-
cific NF-kB-binding nonlabeled oligonucleotide (specific competitor)
or a p53-binding nonlabeled oligonucleotide (nonspecific competitor)
was added to the binding-reaction mixtures for 10 min before the
addition of the specific 32P-labeled NF-kB-binding oligonucleotide. In
the last lane, the undiluted anti-p65/RelA (C-20 from Santa Cruz)
antibody was added in 1/10 of the final reaction volume for 10 min
before the addition of the specific 32P-labeled NF-kB-binding oligo-
nucleotide. Addition of several irrelevant antibodies did not interfere
with the specific binding of NF-kB to DNA, demonstrating the spec-
ificity of the anti-p65/RelA antibody-induced supershift (data not
shown).
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the aid of a lipophilic internalization vehicle) was severely
impaired in its ability to induce beta interferon expression in
the pkr0/0(EX213) MEF (76) or in a pkr0/0(EX213) 3T3-like
fibroblast cell line (11). We investigated whether PKR might
be required for the dsRNA-induced expression of beta inter-
feron when dsRNA was delivered with the aid of Lipofectin.
Treatment with dsRNA for 4 h led to the accumulation of the
mRNA for beta interferon (as measured in an RNase protec-
tion assay) in the pkr1/1(EX213), pkr0/0(EX213), pkr1/1
(EX12), and pkr0/0(EX12) MEF (Fig. 7A, lanes 3, 6, 9, and 12).
Determination of the actual fold activation was impossible due
to the undetectable levels of beta interferon mRNA expression
in the control cells (lanes 1, 4, 7, and 10). Similar to beta
interferon, the mRNAs for two inflammatory cytokines, IL-6
and TNF-a, were also induced by dsRNA in the pkr1/1
(EX213), pkr0/0(EX213), pkr1/1(EX12), and pkr0/0(EX12)
MEF (lanes 3, 6, 9, and 12). In contrast, the mRNAs encoding
the cytokines transforming growth factor b3 (TGF-b3) and
migration inhibitory factor (MIF) were expressed constitu-
tively in the MEF and were not induced by dsRNA, demon-
strating the specificity of the dsRNA response (lanes 3, 6, 9,
and 12). None of these mRNAs was induced by Lipofectin
alone (lanes 2, 5, 8, and 11). We concluded, therefore, that
PKR was not required for the dsRNA-induced expression of
FIG. 6. dsRNA-induced specific DNA-binding activity of NFkB in-
dependent of the presence or the absence of PKR. (A) pkr1/1(EX12)
or pkr0/0(EX12) MEF were treated with Lipofectin alone (lanes Con-
trol), with pI-pC (10 mg/ml) in the presence of Lipofectin (lanes
dsRNA), or with TNF-a (lanes TNF). At the indicated times after the
treatment, the cells were harvested and EMSAs were performed as in
the experiment in Fig. 5. A specific 32P-labeled NF-kB-binding oligo-
nucleotide (top panel) or 32P-labeled oligonucleotide bearing a single-
base substitution (Santa Cruz) (middle panel) was used. The asterisk
depicts the position in the middle panel that corresponds to the posi-
tion of the NF-kB-DNA complex in the upper panel. The correspond-
ing cytosolic extracts (see Materials and Methods) were used in an
immunoblot procedure to demonstrate the absence of PKR in the
pkr0/0(EX12) MEF (bottom panel). (B) pkr1/1(EX12) or pkr0/0(EX12)
MEF were left untreated (lanes Control) or were treated with pI-pC
(100 or 500 mg/ml) in the absence of Lipofectin (lanes dsRNA), with
Lipofectin alone (lane LF), or with pI-pC (10 mg/ml) in the presence
of Lipofectin (lane LF1dsRNA). At the indicated times after the
treatment, the cells were harvested and EMSAs were performed as in
the experiment in Fig. 5.
FIG. 7. Expression of dsRNA-induced genes independent of the
presence or absence of PKR. (A) MEF with the indicated genotype
were left untreated (lanes Control) or were treated with Lipofectin
alone (lanes LF) or with pI-pC (10 mg/ml) in the presence of Lipofec-
tin (lanes dsRNA). At 4 h later, the cells were harvested, total RNA
was prepared, and the steady-state levels of expression of multiple
cytokines were assessed in a multiprobe RNase protection assay as
described in Materials and Methods. The levels of the mRNAs for the
ribosomal protein L32 and the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were used as controls for RNA
amount and loading. TGFb3, transforming growth factor b3; MIF,
migration inhibitory factor. (B) MEF with the indicated genotype were
treated with Lipofectin alone (2) or with pI-pC (10 mg/ml; dsRNA) in
the presence of Lipofectin (1). At 24 h later, the presence of IL-6 in
the conditioned culture medium was determined as described in Ma-
terials and Methods. Error bars represent standard deviation from
experimental points in triplicate.
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beta interferon mRNA or of IL-6 and TNF-a mRNAs. PKR
was also not required for the dsRNA-induced accumulation of
the mRNA for the NF-kB-dependent antiapoptotic gene iap-2
(data not shown).
PKR contributes, in mouse fibroblasts, about 50% of the
overall inhibition of translation in response to dsRNA (the
other 50% being contributed by the 2-5 oligoadenylate syn-
thase/RNase L system) (26). It was therefore reasonable to
speculate that activated PKR may negatively affect gene ex-
pression via its inhibitory action on protein synthesis. To ad-
dress this question, we employed a highly sensitive enzyme-
linked immunosorbent assay for the detection of IL-6 and
determined whether the presence or absence of PKR affects
the expression and/or secretion of this cytokine. As shown in
Fig. 7B, the levels of IL-6 in the culture medium were markedly
elevated 24 h after the treatment with dsRNA in the pkr1/1
(EX213), pkr0/0(EX213), pkr1/1(EX12), and pkr0/0(EX12)
MEF. We were unable, therefore, to discern a clear pattern of
PKR involvement in the production of IL-6 in response to
dsRNA.
The dsRNA-induced activation of NF-kB does not require
RNase L. The OAS/2-5A/RNase L system is a dsRNA-acti-
vated signal transduction cascade that parallels the PKR/
eIF-2a cascade (54). In mouse fibroblasts, PKR and RNase L
are solely required and sufficient for the dsRNA-induced inhi-
bition of translation, since cells with a combined deficiency in
both genes fail to inhibit translation when challenged with
dsRNA (26). We considered the possibility that RNase L
might be involved in mediating the dsRNA-induced signaling
to NF-kB. To test this hypothesis, we employed 3T3-like fibro-
blast cell lines with pkr1/1/rnasel1/1, pkr1/1/rnasel2/2, and
pkr2/2/rnasel2/2 genotypes (84). Both the cells with a single
RNase L deficiency and the cells with a combined PKR and
RNase L deficiency displayed dsRNA-induced degradation of
IkB-b in a manner similar to the wild-type cells (Fig. 8, com-
pare lanes 1 to 3 with lanes 4 to 6). Furthermore, in each cell
line, NF-kB translocated to the nucleus in response to dsRNA
treatment (Fig. 9). We concluded, therefore, that neither PKR
nor RNase L is a critical component in mediating the dsRNA-
induced signaling to NF-kB.
DISCUSSION
The most important result of this study is the demonstration
of a novel response of cells to viral dsRNA that is independent
of the dsRNA-activated PKR. Surprisingly, we found that this
response includes the dsRNA-induced activation of NF-kB
(Fig. 2 to 6, 8, and 9) and the production of beta (“fibroblast”)
interferon (Fig. 7A), two critical components of innate immu-
nity that were previously described by others to depend, in
fibroblasts, on the presence of PKR (11, 76, 79). We argue that
the activation of NF-kB by dsRNA does not require PKR
because the following critical steps of activation of this tran-
scription factor by dsRNA were found to be unimpaired in
cells lacking PKR: (i) the phosphorylation, polyubiquitinyla-
tion, and degradation of IkB (Fig. 2); (ii) the nuclear translo-
cation of NF-kB (Fig. 4); (iii) the specific DNA-binding activity
of NF-kB (Fig. 6); and (iv) the induction of NF-kB-dependent
FIG. 8. dsRNA-induced degradation of IkB-b in cells deficient in
RNase L or both RNase L and PKR. 3T3-like fibroblast cell lines with
pkr1/1/rnasel1/1, pkr1/1/rnasel2/2, and pkr2/2/rnasel2/2 genotypes
were treated with Lipofectin alone (lanes Control) or with pI-pC (10
mg/ml) in the presence of Lipofectin (lanes dsRNA). At the indicated
times after treatment, the cells were harvested and the steady-state
levels of IkB-b were assessed as in the experiment in Fig. 1A. The
membranes were stripped and reprobed with an anti-PKR antibody
(D-20).
FIG. 9. dsRNA-induced nuclear translocation of NFkB in cells de-
ficient in RNase L or both RNase L and PKR. 3T3-like fibroblast cell
lines with pkr1/1/rnasel1/1, pkr1/1/rnasel2/2, and pkr2/2/rnasel2/2 ge-
notypes were treated with Lipofectin alone (Control) or with pI-pC (10
mg/ml) in the presence of Lipofectin (dsRNA). At 3 h after treatment,
the cells were fixed and immunostained with an antibody recognizing
the p65/RelA subunit of NFkB as in the experiment in Fig. 3.
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genes, such as the genes for beta interferon, IL-6, TNF-a, and
IAP-2 (Fig. 7 and data not shown) (for an extended list of
established NF-kB-dependent genes, see reference 42 and ref-
erences therein).
Evidence for the existence of previously unsuspected novel
cellular sensors for dsRNA and their implication in the anti-
viral response and postviral immunopathic diseases. Figure 10
summarizes the model we propose for the ability of viral
dsRNA to trigger both pro- and antiapoptotic cellular pro-
grams. The apoptotic program requires the activities of PKR
and RNase L (see below). Based on our findings that the
antiapoptotic program of innate antiviral immunity (which
proceeds through the activation of NF-kB) is independent of
the presence of PKR and RNase L, we postulate the existence
of novel, yet to be identified sensors for dsRNA that are dif-
ferent from PKR and, probably, OAS. It is possible that the
same novel dsRNA-sensing machinery also mediates the virus-
induced activation of the SAPK (i.e., JNK and p38 MAP ki-
nase), since the dsRNA-induced activation of SAPK can also
proceed in the absence of PKR and RNase L (26). The acti-
vation of NF-kB is thought to mediate cell survival in response
to viral infection (48). The combined activation of SAPK and
NF-kB, in turn, is probably involved in the production of alpha,
beta, and omega interferons and other alarmones, including
inflammatory mediators such as IL-6 and TNF-a. Concerning
the role of inflammatory cytokines induced by dsRNA, we
hypothesize that the PKR-independent, dsRNA-induced acti-
vation of the SAPK- and NF-kB-dependent signal transduction
pathways (which lead to the expression of inflammatory medi-
ators [reference 26 and this study]) may be an important con-
tributor not only to the acute inflammation but also to the
chronic inflammation caused by persistent viral infections.
Enteroviruses (such as coxsackievirus, poliovirus, echovirus,
EMCV, and other members of the picornavirus family; for a
review, see reference 47) are known to cause debilitating and
long-lasting postviral immunopathic muscle diseases. For in-
stance, the coxsackievirus-induced mouse model of inflamma-
tory myopathy is associated with the presence in the affected
muscle of persistent dsRNA viral sequences (60). Wessely et
al. (71) have used transgenic expression of both the plus and
minus strands of a replication-restricted coxsackievirus ge-
nome in the mouse heart to provide experimental evidence
that coxsackievirus dsRNA can cause dilated cardiomyopathy
in the absence of infectious viral progeny. Heart failure due to
dilated cardiomyopathy accounts for ;45% of the cardiac
transplantations performed in the United States (23). An in-
vestigation of the involvement of dsRNA-induced SAPK- and
NF-kB-dependent signal transduction pathways in virus-in-
duced inflammatory myopathies may therefore have important
therapeutic consequences.
Is there an irreconcilable difference between our finding
that PKR is not required for the dsRNA-induced signaling to
NF-kB and interferon production and the results of others
who have reached the opposite conclusion? In our opinion,
there is not an irreconcilable difference between our results
and those of other workers (11, 76, 79). The best evidence for
this is the indication (already contained in the work of Yang et
al. 76) that PKR is not involved in mediating the innate im-
munity to viruses at the level of the organism. In that study, the
authors found that injection of dsRNA peritoneally into either
PKR-containing or PKR-deficient mice induced similar levels
of beta interferon mRNA expression in the spleens of the mice
of either genotype (76). However, we are currently unable to
offer an explanation for the differences between our results and
the results of Williams and coworkers and Karin and cowork-
ers (11, 76, 79) in experiments performed in MEF in vitro.
Still, could PKR, under specific circumstances, play a role in
the activation of NF-kB by viral dsRNA? Several recent re-
ports indicate that this is possible. It has been discovered that
when overexpressed in cells, PKR has the potential to activate
IKK2/b (6, 11, 19). Interestingly, a kinase-deficient mutant of
PKR retained the ability to activate IKK2/b upon overexpres-
sion, suggesting that in this case, PKR exerted a kinase-inde-
pendent action whose nature is unknown (6, 11). It remains to
be elucidated whether this phenomenon has biological rele-
vance.
What is the major role of PKR (and of the OAS/RNase L
system) in response to virus infections? Obviously, the most
relevant answers to this question should come from the PKR
and RNase L genetic knockouts. The most profound defects
we observed in fibroblasts that are deficient in PKR, RNase L,
or both PKR and RNase L were the reduced ability of dsRNA
to inhibit translation (26) and to trigger apoptosis (our unpub-
lished observations). These results alone establish both PKR
and OAS/RNase L system as important mediators of the pro-
apoptotic cellular program in response to virus infections. Ad-
ditional confirmation of the proapoptotic role of PKR and
RNase L comes from the attempts of several laboratories to
establish cell lines overexpressing either of these two enzymes.
Overexpression of either PKR or RNase L potentiates apopto-
sis in response to dsRNA (2, 3, 7, 9, 78). Interestingly, PKR-
FIG. 10. Model for the diverse actions of viral dsRNA at the cel-
lular level. See explanations in the text.
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overexpressing cells are also more sensitive to the cytotoxic
effects of TNF-a (78), an effect probably resulting from an
increased sensitivity to apoptotic stimuli in the face of com-
promised sustainability of the process of protein synthesis. Is
the PKR-mediated inhibition of protein synthesis per se a main
cause of PKR-induced apoptosis? Some experimental evidence
suggests that this may be the case. For instance, apoptosis
induced by an overexpression of PKR could be counteracted
by the concomitant overexpression of a nonphosphorylatable
form of eIF-2a (20, 53). Furthermore, expression of a mutant
form of eIF-2a that mimics phosphorylated eIF-2a was found
to induce apoptosis by itself (53).
Finally, although the evidence provided in this study does
not support a role for PKR in mediating the expression of
NF-kB-dependent genes, our conclusions should not be inter-
preted as an attempt to rule out the possible participation of
PKR in signal transduction to the nucleus. Further studies,
especially those using powerful DNA array technologies, are
likely to provide a conclusive answer in the near future. Fur-
thermore, we have recently reported that the PKR- and RNase
L-mediated inhibition of protein synthesis (but not PKR and
RNase L per se) plays a critical role in the ability of dsRNA to
trigger the activation of JNK (26). This establishes the inter-
esting possibility that dsRNA-activated JNK may play a role in
mediating dsRNA-induced apoptosis. This possibility is cur-
rently being investigated.
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